Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies

Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies

Effective oncolytic virotherapy may require systemic delivery, tumor targeting, and resistance to virus-neutralizing (VN) antibodies. Since herpes simplex virus (HSV) glycoprotein D (gD) is the viral attachment/entry protein and predominant VN target, we examined the impact of gD retargeting alone a...

Full description

Bibliographic Details
Main Authors: Ceren Tuzmen, Tina M. Cairns, Doina Atanasiu, Huan Lou, Wan Ting Saw, Bonnie L. Hall, Justus B. Cohen, Gary H. Cohen, Joseph C. Glorioso
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050120300048

Internet

http://www.sciencedirect.com/science/article/pii/S2329050120300048

Similar Items